McKesson FY2027 Q2: revenue $111.0B, adjusted EPS up 18%
McKesson's FY2027 Q2 supports a Bullish view: revenue reached $110.96 billion, adjusted EPS rose 18.0% to $11.68, and management raised full-year adjusted EPS guidance. Read the quarter through the 3.6% gross margin and the working-capital balance sheet, because this is a high-volume, low-margin distributor where cash conversion and buybacks do much of the per-share work.
1 · Expected vs. Actual
Free preview belowGAAP EPS was $10.44, up $1.52 from $8.92, while adjusted EPS was $11.68, up 18.0% from $9.86. Adjusted earnings were $1.36 billion versus $1.23 billion, and the diluted share count fell to 116.7 million from 124.4 million. That share-count drop is a real part of the per-share story, so read EPS alongside the $3.6 billion first-half capital return.
Revenue was $110.96 billion, up 8.0% from $103.15 billion a year ago. The press release attributes the increase to higher prescription volumes and specialty-product distribution in North American Pharmaceutical and Oncology & Multispecialty, partly offset by lower branded-pharmaceutical contributions. Gross margin was 3.6%, versus 3.4% a year ago, so the mix is still thin but slightly better.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-11-04
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.